For health care professionals in EUROPE excepted those practicing in France as the following pages are intended to all International health care professionals and are not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Other health care professionals should select their country in the top right corner of the website.

Please note that the following pages are exclusively reserved for health care professionals in countries with applicable health authority product registrations. To the extent this site contains information, reference guides and databases intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions.

This Website is protected by the laws on copyright and by the relevant international conventions. It is strictly forbidden to make copies, whether partial or total and on whichever media without prior approval.


LINC 2023

Explore our Endovascular Solutions​

6 – 9 June​

More evidence. More confidence. More successful outcomes.

Discover us at the LINC 2023 Congress, a renowned gathering of healthcare professionals from around the world!​

Find out our endovascular cutting-edge scientific activities through our global team of experts, committed to unlocking life-changing outcomes for patients. ​

Visit us at booth #5.​

Follow us on LinkedIn and Twitter

Join the online conversation and use #LINC2023​

Arterial Symposium

Join the conversation with our global panel of professionals, who will share their knowledge and perspectives on the latest evidence on the fight against Peripheral Artery Disease (PAD). 


Chairs: Prof. Brodmann and Prof. Deloose​


  • Prof. Brodmann: RCT data, the pinnacle of proof​

  • Prof. Torsello: Real world data​

  • Dr. Iida: Real world data from Japan​

  • Prof. Gouëffic: Big data from big databases​

  • All: Where we have been, what we have learnt, where we are going​

Live Case Session​

Dr. Tatsuya Nakama

Complex SFA ​ intervention

LINC 2023 features our exclusive Live Case session performed by 
Dr. Tatsuya Nakama from Tokyo Bay

Jetstream™ Workshop​

Dr Arun Kumarasamy

Exclusive participation

Find out more about the Jetstream™ Atherectomy System with Dr Arun Kumarasamy on:​
Tuesday 6th of June, 13:30 – 15:30​
Wednesday 7th  of June, 11:00 – 13:00


Support when you need it, where you need it​

If you want to dive deeper into our ExpertLink Remote Connectivity solutions, swing by our booth for more information.​

Learn more about our technologies

Featured Products​


Eluvia™ Drug-Eluting Vascular Stent System ​

Eluvia™ is developed for the treatment of PAD and provides durable outcomes in challenging SFA disease, through a polymer design for controlled drug release. ​​

Eluvia Drug-Eluting Stent


Ranger™ Drug Coated Baloon

Ranger™ treats PAD patients in the SFA and PPA. It was designed to provide consistent and predictable drug delivery through efficient drug transfer, and a strong coating integrity.​​

Ranger Drug-Coated Balloon


AVVIGO™ GuidanceSystem II (IVUS) ​

AVVIGO™ is a streamlined flexible multi-modality guidance system platform that features intuitive software that offers high-definition IVUS images, using OptiCross™ 18 and OptiCross™ 35 Peripheral Imaging Catheters.​

AVVIGO™ Guidance System II

Drug-Eluting Technologies​

Occlusive disease in the Superficial Femoral Artery (SFA) remains challenging because of the high rates of restenosis8. Restenosis following SFA treatment is prevalent and depends on the choice of therapy. ​​

Boston Scientific offers the only drug-eluting technologies backed by 5 RCTs, and studies that will exceed 10,000 patients1-6 Our SFA portfolio includes all the devices needed to access, prepare and treat any type of lesion. ​​

The advanced technologies of drug-coated balloons and drug-eluting stents have been proven to lower the risk of restenosis compared to non-drug devices2,7 enabling to optimise outcomes for patients.​

  1. Sachar R et al. RANGER II SFA Investigators. 1-year results from the RANGER II SFA randomized trial of the Ranger drug-coated balloon. JACC Cardiovasc Interv. 2021;10:1123–1133.​​

  2. ​Gouëffic Y, et al. Efficacy of a drug-eluting stent versus bare metal stents for symptomatic femoropopliteal peripheral artery disease: Primary results of the EMINENT randomized trial. Circulation. 2022;146:1564–1576.​​

  3. ​Steiner S, et al. 12-month results from the first-in-human randomized study of the ranger paclitaxel-coated balloon for femoropopliteal treatment. JACC Cardiovasc Interv. 2018;11:934–941.​​

  4. Steiner S, et al. COMPARE: prospective, randomized, non-inferiority trial of high- vs. low-dose paclitaxel drug-coated balloons for femoropopliteal interventions. Eur Heart J. 2020;41:2541–2552.​​

  5. ​Müller-Hülsbeck S, et al. Two-year efficacy and safety results from the IMPERIAL Randomized study of the Eluvia polymer-coated drug-eluting stent and the Zilver PTX polymer-free drug-coated stent. Cardiovasc Intervent Radiol. 2021;44:368–375.​​

  6. Marianne Brodmann, CIRSE 2022 Symposium: DET in complexities co-morbidities, and underserved patient populations.​​

  7. ​Ullah W, et al. Safety and efficacy of drug-coated balloon for peripheral artery revascularization-A systematic review and meta-analysis. Catheter Cardiovasc Interv. 2022;99(4):1319–1326.​

  8. Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M et al; Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: Circ Cardiovasc Interv. 2010 Jun 1; 3(3): 267-276. doi: 10.1161/CIRCINTERVENTIONS.109.903468 ​

The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.